Y-mAbs Therapeutics' (YMAB) Outperform Rating Reiterated at Wedbush

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report)'s stock had its "outperform" rating restated by analysts at Wedbush in a research note issued on Wednesday, Marketbeat Ratings reports. They currently have a $18.00 price target on the stock, down from their prior price target of $21.00. Wedbush's price objective suggests a potential upside of 282.17% from the company's current price.

Several other equities research analysts have also recently commented on YMAB. Bank of America cut Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price target for the company. in a research note on Tuesday, April 22nd. Oppenheimer cut their price objective on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a research report on Wednesday, May 14th. Truist Financial lowered their target price on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Morgan Stanley dropped their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research note on Wednesday, March 5th. Finally, HC Wainwright cut their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a report on Monday, May 19th. Two analysts have rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Y-mAbs Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $15.60.

Y-mAbs Therapeutics Trading Down 0.8%

Shares of NASDAQ YMAB traded down $0.04 during trading hours on Wednesday, reaching $4.71. The stock had a trading volume of 253,129 shares, compared to its average volume of 308,587. The firm has a 50-day moving average of $4.37 and a 200-day moving average of $6.33. The firm has a market cap of $213.29 million, a price-to-earnings ratio of -8.72 and a beta of 0.53. Y-mAbs Therapeutics has a fifty-two week low of $3.55 and a fifty-two week high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.10. The firm had revenue of $20.90 million for the quarter, compared to analysts' expectations of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. On average, equities analysts predict that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Insider Transactions at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the transaction, the insider now owns 202,721 shares in the company, valued at approximately $1,060,230.83. The trade was a 5.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 22.50% of the company's stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Brooklyn Investment Group increased its position in Y-mAbs Therapeutics by 4,563.8% during the first quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock worth $26,000 after buying an additional 5,796 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Y-mAbs Therapeutics during the fourth quarter valued at $46,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Y-mAbs Therapeutics during the 1st quarter worth about $49,000. Corton Capital Inc. acquired a new position in Y-mAbs Therapeutics in the 1st quarter valued at about $55,000. Finally, EntryPoint Capital LLC purchased a new position in Y-mAbs Therapeutics in the 1st quarter valued at about $56,000. Hedge funds and other institutional investors own 70.85% of the company's stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.